Study on Painful Thumb Osteoarthritis: Comparing Triamcinolone Acetonide, Sodium Chloride, and Occupational Therapy for Patients with Inflammatory Thumb Joint Pain

1 1 1

What is this study about?

This clinical trial is focused on studying the effects of treatments for osteoarthritis in the base joint of the thumb, known as the first carpometacarpal joint. Osteoarthritis is a condition that causes pain and swelling in the joints. The study will explore the effectiveness of different treatments, including an injection of a medication called Kenacort-T, which contains the active ingredient triamcinolone acetonide, and a saline solution, which is a mixture of water and sodium chloride. Additionally, the study will evaluate the benefits of occupational therapy, which involves exercises and techniques to improve hand function.

The purpose of the study is to determine if the steroid injections are more effective than saline injections after four weeks and to compare the results of all three treatments after twelve weeks. Participants will receive one of these treatments through an injection directly into the affected joint. The study will monitor changes in pain and joint function over time, using simple scales to measure pain levels and other symptoms.

Participants will be observed over a period of several weeks to assess how their symptoms change with each treatment. The study aims to provide valuable information on which treatment might offer the best relief for those suffering from painful thumb base osteoarthritis. This information could help guide future treatment options for patients with this condition.

1 initial assessment

Upon joining the trial, an initial assessment is conducted to confirm eligibility. This includes verifying age between 40-85 years, confirming osteoarthritis in the first carpometacarpal joint through radiographs or ultrasound, and assessing pain levels in the joint.

2 treatment allocation

Participants are randomly assigned to one of three treatment groups: intraarticular corticosteroid injections, saline injections, or a multimodal occupational therapy intervention.

3 treatment administration

For those receiving injections, the treatment involves an intra-articular injection into the joint. The corticosteroid used is triamcinolone acetonide (Kenacort-T 40 mg/ml), and the saline solution is sodium chloride (Natriumklorid Fresenius Kabi 9 mg/ml).

4 follow-up assessments

Follow-up assessments occur at various intervals: 4 weeks, 12 weeks, 24 weeks, and 104 weeks. These assessments measure changes in pain, joint function, and overall disease activity using a Numeric Rating Scale (NRS) and other evaluation tools.

5 primary outcome evaluation

The primary outcome is evaluated by assessing changes in thumb base joint pain during activities over the last 24 hours, measured at 4 weeks and 12 weeks.

6 secondary outcome evaluation

Secondary outcomes include changes in pain in finger joints, grip strength, use of pain relief medications, and patient satisfaction. These are assessed at multiple time points throughout the trial.

7 completion of trial

The trial is estimated to conclude by October 2027. Final assessments will be conducted to evaluate long-term effects and any adverse events experienced during the trial.

Who Can Join the Study?

  • Men and women between 40-85 years of age
  • Have osteoarthritis in the target CMC-1 joint, which is confirmed by X-rays or an ultrasound. Osteoarthritis is a condition that affects the joints, causing pain and stiffness.
  • Have inflammation in the target CMC-1 joint, confirmed by an ultrasound showing a grey scale synovitis grade of 1-3. Inflammation is the body’s response to injury or irritation, often causing redness, warmth, swelling, and pain.
  • Experience pain in the target CMC-1 joint with a score of at least 3 on a 0-10 Numeric Rating Scale (NRS) at rest or during activities, both at pre-screening and screening. The Numeric Rating Scale is a way to measure pain intensity, where 0 means no pain and 10 means the worst possible pain.
  • Assessed as eligible for the proposed use of Kenacort-T, a medication used in the treatment.

Who Cannot Join the Study?

  • Patients who have had surgery on the affected joint in the past 6 months cannot participate.
  • Patients with an infection in the affected joint are not eligible.
  • Patients who have received a corticosteroid injection in the affected joint within the last 3 months are excluded.
  • Patients with a known allergy to corticosteroids or any component of the injection cannot join the study.
  • Patients with a history of severe allergic reactions, known as anaphylaxis, to any medication are not eligible. Anaphylaxis is a serious and rapid allergic reaction that can be life-threatening.
  • Patients who are currently participating in another clinical trial are not allowed to join this study.
  • Patients with a condition that, in the opinion of the investigator, would interfere with the study results or the patient’s safety are excluded.
  • Pregnant or breastfeeding women cannot participate in the study.
  • Patients with uncontrolled diabetes or other uncontrolled medical conditions are not eligible. Uncontrolled means the condition is not being managed well with treatment.
  • Patients with a history of drug or alcohol abuse in the past year are excluded.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name City Country Status
St. Olavs Hospital HF Trondheim Norway
Helse Stavanger HF Stavanger Norway
Nordlandssykehuset HF Bodo Norway
Diakonhjemmet Sykehus AS Oslo Norway
Martina Hansens Hospital AS Gjettum Norway
Haugesund Sanitetsforenings Revmatismesykehus AS Haugesund Norway

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Norway Norway
Recruiting
01.10.2023

Trial locations

Corticosteroid Injections are used in this trial to reduce inflammation and pain in the joint. They are injected directly into the affected area to provide relief from symptoms associated with osteoarthritis.

Saline Injections are used as a comparison treatment in this trial. They involve injecting a saltwater solution into the joint, which does not have active therapeutic effects but helps to evaluate the effectiveness of the corticosteroid injections.

Occupational Therapy Intervention is a non-drug treatment included in the trial. It involves various techniques and exercises designed to improve hand function and reduce pain in patients with osteoarthritis of the thumb joint.

Investigated diseases:

Osteoarthritis in the first carpometacarpal joint – This condition involves the degeneration of cartilage in the joint at the base of the thumb, leading to pain and stiffness. It is a common form of arthritis that affects the hands, particularly in older adults. As the cartilage wears down, bones may rub against each other, causing discomfort and reduced range of motion. Over time, the joint may become swollen and tender, and activities that require thumb movement can become challenging. The progression of the disease can lead to changes in joint structure, such as the development of bone spurs. This condition can significantly impact hand function and daily activities.

Trial ID:
2023-505254-17-00
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • A study comparing montelukast to placebo for reducing pain in patients with erosive osteoarthritis of the hands

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Italy Portugal Spain
  • Efficacy of intra‑articular allogeneic peripheral blood mononuclear cells induced to an early apoptotic state versus placebo in adults with primary knee osteoarthritis

    Recruiting

    Denmark